<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427724</url>
  </required_header>
  <id_info>
    <org_study_id>STU200401</org_study_id>
    <nct_id>NCT02427724</nct_id>
  </id_info>
  <brief_title>The Effect of Topical Anesthetics on Patients' Pain and Operative Experience During Treatment With QSwitched Laser</brief_title>
  <official_title>The Effect of Topical Anesthetic Using Lidocaine 2.5%/Prilocaine 2.5% Versus Lidocaine 7%/Tetracaine 7% Cream on Patients' Pain and Operative Experience During Treatment With QSwitched 532nm Laser</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will conduct a split-face and -body randomized control trial to compare lidocaine&#xD;
      2.5%/prilocaine 2.5% topical anesthetic (LPTA), lidocaine 7%/tetracaine 7% topical anesthetic&#xD;
      (LTTA), and placebo vechicle (PV) on patients' pain perceptions with Q-switched 532nm laser&#xD;
      for the treatment of lentigines and/or photorejuvenation.Subjects will fill out a pain score&#xD;
      on a visual analog scale (VAS) with 0 being no pain and 10 being most pain after each&#xD;
      treatment area is completed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual analog score (VAS) pain rating</measure>
    <time_frame>Day of treatment</time_frame>
    <description>Subjects will fill out a visual analog score (VAS) pain rating after treatment with 0 being no pain and 10 being worst pain</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Lentigo</condition>
  <arm_group>
    <arm_group_label>lidocaine 2.5%/prilocaine 2.5% topical anesthetic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lidocaine 7%/tetracaine 7% topical anesthetic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine 2.5%/prilocaine 2.5% topical anesthetic</intervention_name>
    <arm_group_label>lidocaine 2.5%/prilocaine 2.5% topical anesthetic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine 7%/tetracaine 7% topical anesthetic</intervention_name>
    <arm_group_label>lidocaine 7%/tetracaine 7% topical anesthetic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo vehicle</intervention_name>
    <arm_group_label>placebo vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Q-switched 532nm Laser</intervention_name>
    <arm_group_label>lidocaine 2.5%/prilocaine 2.5% topical anesthetic</arm_group_label>
    <arm_group_label>lidocaine 7%/tetracaine 7% topical anesthetic</arm_group_label>
    <arm_group_label>placebo vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who have moderate lentigines and/or photodamage and desire laser toning.&#xD;
&#xD;
          2. Females 25-65 years of age.&#xD;
&#xD;
          3. In good health.&#xD;
&#xD;
          4. Have Fitzpatrick phototype I-III.&#xD;
&#xD;
          5. Willingness and the ability to understand and provide informed consent and communicate&#xD;
             with the investigator/study staff.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Younger than 25 or older than 65 years of age.&#xD;
&#xD;
          2. Pregnant or lactating.&#xD;
&#xD;
          3. Is a male.&#xD;
&#xD;
          4. Has received the following treatments on the face:&#xD;
&#xD;
               -  ablative or non-ablative laser procedure in the past 3 months&#xD;
&#xD;
               -  radiofrequency device treatment in the past 3 months&#xD;
&#xD;
               -  ultrasound device treatment in the past 3 months&#xD;
&#xD;
               -  medium to deep chemical peel in the past 3 months&#xD;
&#xD;
          5. Has an active infection on the face or upper inner arms (excluding mild acne).&#xD;
&#xD;
          6. Is allergic to lidocaine, tetracaine, or prilocaine.&#xD;
&#xD;
          7. Has kidney disease and/or liver disease.&#xD;
&#xD;
          8. Has G-6-PD and/or pseudocholinesterase deficiency.&#xD;
&#xD;
          9. Is taking a class I anti-arrhythmic medication.&#xD;
&#xD;
         10. Is tanned.&#xD;
&#xD;
         11. Has a history of hyperpigmentation with laser treatment.&#xD;
&#xD;
         12. Has a mental illness.&#xD;
&#xD;
         13. Has a history of a chronic pain condition such as fibromyalgia or vulvodynia.&#xD;
&#xD;
         14. Unable to understand the protocol or to give informed consent.&#xD;
&#xD;
         15. Multiply recurrent episodes of cold sores.&#xD;
&#xD;
         16. Any significant skin disease beyond mild acne.&#xD;
&#xD;
         17. Any other condition that would, in the professional opinion of the investigator,&#xD;
             potentially affect response or participation in the clinical clinical study, or would&#xD;
             pose as an unacceptable risk to the subject.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murad Alam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine, Department of Dermatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Murad Alam</investigator_full_name>
    <investigator_title>Professor in Dermatology, Otolaryngology-Head and Neck Surgery, and Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lentigo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Tetracaine</mesh_term>
    <mesh_term>Prilocaine</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

